Prescient Therapeutics: Q&A Update with Professor H. Miles Prince
Reach Markets recently interviewed Professor H. Miles Prince AM – the Principal Investigator of our PTX-100 program – regarding its phase 1b trial and the encouraging outcomes it is delivering for patients.
In the video, Professor Prince discusses how:
- PTX100 targets an elusive pathway in treating T-cell lymphomas, offering hope for conditions like cutaneous T-cell lymphoma with limited options.
- The phase 1 study showed a [near] 50% response rate with prolonged remissions lasting beyond six months and, in some cases, several years.
- The drug is really safe, and there is optimism about its potential for expedited regulatory approval given the unmet clinical need.
Recorded on 8 December 2024 at 12:00pm (AEDT)
Featured Speaker
Professor H. Miles Prince
Hematologist and Professor of Medicine
Professor H. Miles Prince is an internationally recognised Australian hematologist and a Professor at both Melbourne and Monash Universities. He is also the Professor/Director of Molecular Oncology and Cancer Immunology at the Epworth Centre, and a Hematologist at the Peter MacCallum Cancer Centre. As a global expert in T-cell lymphomas, Professor Miles acts as the Principal Investigator for the PTX-100 clinical trials. He holds major Australian, American and European research grants and has published over 450 journal articles. In 2014 he was awarded a Member of the Order of Australia (general division) for significant services to blood cancer research, patient care and philanthropy leadership.
